Fluvoxamine, a drug originally indicated for the treatment of mental illnesses such as anxiety and depression, was reduced by five percentage points simply because of hospitalizations in patients with Covid-79, points out a new research.
The study was carried out at 12 Brazilian cities electronic published in the scientific magazine The Lancet Worldwide Wellness.
Gilmar Reis, professor perform department about medicine from PUC-Minas electronic one 2 authors of a research, explain that the Covid-19 causes an inflammatory process to dieses cells in an unrestrained way, causing problems such as respiratory syndromes.
Scientists there knew that fluvoxamine is capable of inhibiting a process of inflammation in the cells. Therefore, the hypothesis that perform medicine will be used in the treatment against the new disease was raised.
” activates an electronic inflammatory process [a fluvoxamina] a medication that inhibits this uncontrolled inflammation”, says one professor.
The study had 1.497 participants all of whom were diagnosed with Covid, had symptoms of an electronic disease, some risk factor such as obesity electronic diabetes The researcher says that this group was chosen because only they are at higher risk
Of the total, 741 participants received fluvoxamine and the others 756 were part of the placebo group.
In the main analysis, each patient took at least one pill and was instructed to use the medication for ten days. At this stage, 119 patients in the placebo group were hospitalized, against 19 among those who took fluvoxamine.
In a second moment, an analysis was made to identify the patients who followed the treatment per set and days. This is because some people end up taking the medicine, regardless of whether they have side effects or not, explains the researcher.
In the end, this subgroup that followed the seven-day protocol was composed of 119 people with use of fluvoxamine and 497 in the placebo group.
“To our surprise, we saw that only one patient had died among those who took the drug against 12 who had died [entre o placebo]”, says Reis about who spent a week using the medicine.
According to him, this data is interesting because it shows that “as patients took the medicine, mortality fell a lot in the group that used it [a flavoxamina]”.
To Otavio Berwanger, director of the Academic Research Organization at Albert Einstein Hospital and author of an editorial on the study , the survey is “a very important and desirable step, but not a final word”.
He says that further investigations are needed to answer some questions about medication, such as what is its effectiveness in vaccinated people j, whether it could be used with other drugs to treat the disease and what is the effect on patients with mild symptoms.
Berwanger still says the drug is not a It is a substitute for vaccines, as it is not a prevention of coronavirus infection. “This drug also requires a prescription and medical follow-up, not a medication that people can take anyway,” he says.